|
| Press Releases |
|
 |
|
| Wednesday, May 20, 2015 |
|
|
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan |
| Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. more info >> |
|
| Thursday, May 14, 2015 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
more info >> |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant ("New Plant") located within the Suzhou Industrial Park in order to relocate and expand its existing OSD production facility ("Old Plant") within the same industrial park. more info >> |
|
|
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint |
| Eisai Co., Ltd. announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, and the study met its primary endpoint. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
WiseChain.io Unveils AI-Powered Social Trading and Tailored Investment Solutions for Canadians and Seniors
Mar 29, 2025 11:00 HKT/SGT
|
|
|
Mobvoi 2024 Annual Results Announcement 
Mar 29, 2025 02:19 HKT/SGT
|
|
|
Dynasty's Profit Attributable to Owners of The Company Increases by 57%
Mar 29, 2025 00:42 HKT/SGT
|
|
|
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 21:51 HKT/SGT
|
|
|
Analogue FY2024 Revenue Rose to HK$6,450 Million with Adjusted Profit Attributable to Owners of the Company Increased to HK$206 Million
Mar 28, 2025 21:21 HKT/SGT
|
|
|
Nissin Foods Announces 2024 Annual Results
Mar 28, 2025 20:56 HKT/SGT
|
|
|
Accelerated Transformation of New Quality Productive Forces with Growing Efficacy in Sci-Tech Innovation Layout
Mar 28, 2025 18:21 HKT/SGT
|
|
|
WL Delicious Announced 2024 Annual Results
Mar 28, 2025 16:55 HKT/SGT
|
|
|
Leading the Future with Reform and Innovation, Embarking on a New Chapter of Global Development
Mar 28, 2025 16:05 HKT/SGT
|
|
|
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
|
|
|
CIMC Group Announces 2024 Annual Results
Mar 28, 2025 14:32 HKT/SGT
|
|
|
Tingyi (Cayman Islands) Holding Corp. 'Dual-wheel Drive of Product Structure & Operational Efficiency' to Enhance Profitability in 2024 with GPM Improving to 33.1% and EBITDA Rising 17.3%
Mar 28, 2025 13:58 HKT/SGT
|
|
|
Sonimedi Captivates the European Beauty Market - Wins 'Best Hair Product' Award at Cosmoprof Bologna 2025
Mar 28, 2025 13:46 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Mar 28, 2025 13:27 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 28, 2025 12:35 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
